"It's critical to have diverse participants in a coronavirus vaccine trial so we know it is effective for populations that are often underrepresented in research", said XinQi Dong, who's directing community recruitment for the Johnson & Johnson trial. They also did not have any serious adverse health events related to the vaccine in the volunteers.
The Lancet report said the first efficacy data from these trials is "possible in the coming weeks". "It's an important point here, in terms of comparing this vaccine to, for instance, the Moderna and Pfizer vaccines". So they included 200 people over 70 to be given the jab.
The results were published in the peer-reviewed journal, The Lancet, on Thursday.
It codes for the spike protein that the coronavirus uses to enter and infect cells in order to train the body to recognized the virus and induce an immune response if infected.
Now, researchers have released preliminary results that show the vaccine produces an immune response, although it's too early to say whether it can prevent disease.
"The next step will be to see if this translates into protection from the disease itself".
According to a report by the BBC, two weeks after the volunteers were administered a second dose, more than 99 percent of them had neutralising antibody responses regardless of age.
Ramasamy told The Guardian that the "robust antibody and T-cell responses" they saw in the group of older people were encouraging.
"We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure".
Older adults were also less likely to experience side-effects, which were usually mild.
Phase 2 trials took place from 3 to 5 May with similar doses but with 300 participants, but production capacity was increased.
Again, participants were separated into two groups for the 14-day and 28-day vaccination schedule and then randomly assigned to receive either a low dose of the vaccine, a high dose, or a placebo. It said one person had a severe reaction of hives and recovered within three days with treatment.
The Oxford vaccine is made from a weakened version of a common cold virus (known as an adenovirus) from chimpanzees that has been modified so it can not grow in humans.
I don't want to come across all Grinch-like, but today's headlines about the Oxford Covid vaccine is not the news we've all been waiting for.
Separately, Pfizer's chief executive Albert Bourla said on Tuesday that the firm plans to submit its vaccine data to the US Food and Drug Administration for emergency-use authorisation.
Results of those trials should definitely be known by Christmas, according to the Oxford Vaccine Group's director, Andrew Pollard.